Home・Aandelen Lijst・Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corp

Gesloten

24.92 5.95

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

24.63

Max

24.92

Belangrijke statistieken
By Trading Economics
Inkomsten	-20M -40M
Verkoop	-9.3M 62M
EPS	-0.1
Winstmarge	-64.64
Werknemers	624
EBITDA	-19M -34M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+0.56% upside

Dividenden
By Acuity
Volgende Winsten	4 nov 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	68M 3.7B
Vorige openingsprijs	18.97
Vorige sluitingsprijs	24.92

Adaptive Biotechnologies Corp Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

8 aug 2026, 23:51 UTC

U.S. Labor Market Contraction Fuels Stock Market Rally and Eases Fed Rate Hike Expectations

8 aug 2026, 23:51 UTC

U.S. equity markets surge to record highs as July job data signals potential pause in Federal Reserve interest rate hikes, while European stocks also reach all-time highs amid mixed economic signals.

8 aug 2026, 23:51 UTC

U.S. equity markets surge to record highs as disappointing July employment data shifts investor sentiment towards a potential pause in Federal Reserve interest rate hikes.

8 aug 2026, 23:51 UTC

U.S. equity markets surge as disappointing July jobs data lowers Fed rate hike expectations, with S&P500 hitting record high.

8 aug 2026, 23:51 UTC

US Producer Price Inflation Expected to Rise 0.1% in July Amid Labor Market Concerns and Fed Rate Speculations

8 aug 2026, 23:51 UTC

Correlated Moves

Macro News

Bitcoin trades higher as a surprising jobs report fuels speculation of interest rate cuts, potentially benefiting cryptocurrencies. Ethereum also sees a slight price increase.

8 aug 2026, 23:41 UTC

Core PPI Release on August 13, 2026, Expected to Show Moderate Inflation Increase Amid Mixed Labor Market Signals and Cautious Investor Sentiment.

8 aug 2026, 23:31 UTC

BoJ's Upcoming Summary of Opinions on August 9, 2026, May Signal Cautious Monetary Policy Amidst Mixed Market Sentiment and Global Rate Hike Discussions.

8 aug 2026, 23:21 UTC

Core Inflation Rate Expected at 2.5% Amid Mixed Economic Data and Job Losses, Influencing Fed's Interest Rate Decisions

8 aug 2026, 23:21 UTC

Core Inflation Rate Release on August 12, 2026 Expected to Show +0.2% Increase Amid Mixed Economic Signals and Job Market Concerns

8 aug 2026, 23:21 UTC

Investors Brace for July CPI Release Amid Mixed Employment Reports and Inflation Concerns Impacting Fed Policy Decisions

8 aug 2026, 23:21 UTC

U.S. Inflation Rate Expected to Rise 0.1% in July Amid Mixed Economic Signals and Labor Market Concerns

8 aug 2026, 23:21 UTC

US CPI YoY Inflation Rate Expected at 3.4% Amid Mixed Economic Signals and Job Losses, Influencing Fed's Interest Rate Decisions

8 aug 2026, 23:21 UTC

Investors Brace for Volatility Ahead of August CPI Release Amid Mixed Economic Signals and Fed Rate Speculation

8 aug 2026, 23:11 UTC

Brazil's Retail Sales Report on August 13 Expected to Reveal Consumer Spending Trends Amid Economic Uncertainties.

8 aug 2026, 22:41 UTC

U.S. 30-Year Mortgage Rates Hit Year-High of 6.81% Amid Weak Job Growth and Fed Rate Speculation

8 aug 2026, 22:41 UTC

Cardano is trading lower today, continuing a downward trend since Friday. The asset remains above its 20-day moving average and near its one-month range high.

8 aug 2026, 22:31 UTC

Brazil's Inflation Rate MoM Release on August 11, 2026, Sparks Caution Among Analysts Amid Global Economic Uncertainties.

8 aug 2026, 22:31 UTC

Brazil's Inflation Rate Release on August 11, 2026 Expected to Reflect Moderate Trends Amid Global Economic Concerns.

8 aug 2026, 22:11 UTC

UK Housing Market Faces Caution Ahead of RICS House Price Balance Release Amid Stagnant Prices and Economic Uncertainty

8 aug 2026, 21:51 UTC

Japan's Current Account Surplus Forecasted at JPY 1,512 Billion Amid Forex Interventions and Cautious Market Sentiment Ahead of August Release.

8 aug 2026, 21:41 UTC

South Korea's unemployment rate expected to hold steady at 2.7% amid global economic uncertainties, with market sentiment cautiously optimistic ahead of August release.

8 aug 2026, 21:31 UTC

UK Retail Sales Monitor YoY for July 2026 Expected to Rise 1.5% Amid Mixed Sentiment and Economic Pressures

8 aug 2026, 21:21 UTC

India's July 2026 Inflation Rate Release Expected to Show Stability at 4.54% Amid Geopolitical Tensions and Food Price Pressures

8 aug 2026, 21:21 UTC

Brazil's Central Bank to announce interest rate decisions amid global economic uncertainties on August 10, 2026.

8 aug 2026, 20:31 UTC

Euro Area's Q2 Employment Change Data Release on August 14 Sparks Cautious Optimism Amid Rising Unemployment and Mixed Economic Signals.

8 aug 2026, 20:31 UTC

Euro Area Expected to Report €2.2 Billion Trade Deficit Amid Mixed Economic Signals and Rising Energy Costs

8 aug 2026, 20:31 UTC

China's Q2 2026 Current Account Data Release Expected to Show Continued Surplus Growth Amidst Global Economic Pressures

8 aug 2026, 20:11 UTC

Eurozone Industrial Production MoM data for June 2026 expected to show flat growth amid concerns over declining output and geopolitical tensions.

8 aug 2026, 20:01 UTC

South Africa's Q2 Unemployment Rate Set for Release Amidst Rising Global Job Concerns, Following Alarming 32.7% in Q1

Peer Vergelijking

Prijswijziging

Adaptive Biotechnologies Corp Prognose

Koersdoel

By TipRanks

0.56% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 25.07 USD 0.56%

Hoogste 28 USD

Laagste 21 USD

Gebaseerd op 8 Wall Street-analisten die 12-maands prijsdoelen bieden voor Adaptive Biotechnologies Corp - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

8 ratings

Buy

Hold

Sell

Gebaseerd op 8 analisten die aandelenratings hebben gegeven aan Adaptive Biotechnologies Corp - Dist in de afgelopen 3 maanden.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.